These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27979840)

  • 1. Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non-Small Cell Lung Cancer.
    Tassi E; Grazia G; Vegetti C; Bersani I; Bertolini G; Molla A; Baldassari P; Andriani F; Roz L; Sozzi G; Pastorino U; Mortarini R; Anichini A
    Cancer Res; 2017 Feb; 77(4):851-861. PubMed ID: 27979840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors.
    Thommen DS; Schreiner J; Müller P; Herzig P; Roller A; Belousov A; Umana P; Pisa P; Klein C; Bacac M; Fischer OS; Moersig W; Savic Prince S; Levitsky V; Karanikas V; Lardinois D; Zippelius A
    Cancer Immunol Res; 2015 Dec; 3(12):1344-55. PubMed ID: 26253731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
    Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
    J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.
    Datar I; Sanmamed MF; Wang J; Henick BS; Choi J; Badri T; Dong W; Mani N; Toki M; Mejías LD; Lozano MD; Perez-Gracia JL; Velcheti V; Hellmann MD; Gainor JF; McEachern K; Jenkins D; Syrigos K; Politi K; Gettinger S; Rimm DL; Herbst RS; Melero I; Chen L; Schalper KA
    Clin Cancer Res; 2019 Aug; 25(15):4663-4673. PubMed ID: 31053602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TIGIT presents earlier expression dynamic than PD-1 in activated CD8
    Hu F; Wang W; Fang C; Bai C
    Exp Cell Res; 2020 Nov; 396(1):112260. PubMed ID: 32890458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.
    Anichini A; Molla A; Vegetti C; Bersani I; Zappasodi R; Arienti F; Ravagnani F; Maurichi A; Patuzzo R; Santinami M; Pircher H; Di Nicola M; Mortarini R
    Cancer Res; 2010 Nov; 70(21):8378-87. PubMed ID: 20861189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD103
    Corgnac S; Malenica I; Mezquita L; Auclin E; Voilin E; Kacher J; Halse H; Grynszpan L; Signolle N; Dayris T; Leclerc M; Droin N; de Montpréville V; Mercier O; Validire P; Scoazec JY; Massard C; Chouaib S; Planchard D; Adam J; Besse B; Mami-Chouaib F
    Cell Rep Med; 2020 Oct; 1(7):100127. PubMed ID: 33205076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8
    Huang B; Liu R; Wang P; Yuan Z; Yang J; Xiong H; Zhang N; Huang Q; Fu X; Sun W; Li L
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
    Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
    J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.
    Djenidi F; Adam J; Goubar A; Durgeau A; Meurice G; de Montpréville V; Validire P; Besse B; Mami-Chouaib F
    J Immunol; 2015 Apr; 194(7):3475-86. PubMed ID: 25725111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
    Matsuzaki J; Gnjatic S; Mhawech-Fauceglia P; Beck A; Miller A; Tsuji T; Eppolito C; Qian F; Lele S; Shrikant P; Old LJ; Odunsi K
    Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7875-80. PubMed ID: 20385810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
    Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
    World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NFATc1 Promotes Antitumoral Effector Functions and Memory CD8
    Heim L; Friedrich J; Engelhardt M; Trufa DI; Geppert CI; Rieker RJ; Sirbu H; Finotto S
    Cancer Res; 2018 Jul; 78(13):3619-3633. PubMed ID: 29691251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
    Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
    J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human CD8
    Machicote A; Belén S; Baz P; Billordo LA; Fainboim L
    Front Immunol; 2018; 9():2788. PubMed ID: 30555473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T-CL.
    Liao Z; Lv X; Liu S; He Z; Chen S; Wang L; Li W; Li Y
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e252-e258. PubMed ID: 29368793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
    Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer.
    Zhang Y; Huang S; Gong D; Qin Y; Shen Q
    Cell Mol Immunol; 2010 Sep; 7(5):389-95. PubMed ID: 20514052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.